Pipeline

TARGETINDICATIONPROGRAMPRECLINICALPHASE IPHASE IIPHASE IIIAPPROVAL
Cerebellar AtaxiasLate-OnsetSLX-1002026
PediatricSLX-2002027
Acute Nerve InjuryTrauma and SurgeryConfidential2029
Chemotherapy NeuropathiesConfidential2030

For SLX-100 and SLX-200, we will be referencing safety and dosing from previously published studies not conducted by Solaxa in our 505b2 expedited regulatory submission

Issued patent protection

6 issued (US, EU & Canada) and 9 pending / provisional patents exclusively licensed

Scroll to Top